Eisen, T., Loembé, A.-B., Shparyk, Y., MacLeod, N., Jones, R.J. , Mazurkiewicz, M., Temple, G., Dressler, H. and Bondarenko, I. (2015) A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 113(8), pp. 1140-1147. (doi: 10.1038/bjc.2015.313) (PMID:26448178) (PMCID:PMC4647871)
|
Text
113571.pdf - Published Version Available under License Creative Commons Attribution. 333kB |
Abstract
background: This exploratory study evaluated the safety/efficacy of nintedanib or sunitinib as first-line therapy in patients with advanced renal cell carcinoma (RCC). methods: Ninety-six patients were randomised (2:1) to either nintedanib (200 mg twice daily) or sunitinib (50 mg kg−1 once daily (4 weeks on treatment; 2 weeks off)). Primary endpoint was progression-free survival (PFS) at 9 months. P-values reported are descriptive only; the study was not powered for such comparisons. results: Progression-free survival at 9 months was comparable between nintedanib and sunitinib (43.1% vs 45.2%, respectively; P=0.85). Median PFS was 8.4 months in each group (hazard ratio (HR), 1.12; 95% confidence interval (CI): 0.70–1.80; P=0.64). Median overall survival was 20.4 and 21.2 months for nintedanib and sunitinib, respectively (HR, 0.92; 95% CI: 0.54–1.56; P=0.76). Overall incidence of any grade adverse events (AEs) was comparable (90.6% vs 93.8%); AEs grade 3 were lower with nintedanib than sunitinib (48.4% vs 59.4%). Nintedanib was associated with lower incidences of some AEs typical of antiangiogenic tyrosine kinase inhibitors (TKIs): hypertension, hypothyroidism, hand–foot syndrome, cardiac disorders and haematological abnormalities. conclusions: In patients with advanced RCC, nintedanib has promising efficacy and similar tolerability to sunitinib, and a manageable safety profile with fewer TKI-associated AEs.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Jones, Professor Robert |
Authors: | Eisen, T., Loembé, A.-B., Shparyk, Y., MacLeod, N., Jones, R.J., Mazurkiewicz, M., Temple, G., Dressler, H., and Bondarenko, I. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | British Journal of Cancer |
Publisher: | Nature Publishing Group |
ISSN: | 0007-0920 |
ISSN (Online): | 1532-1827 |
Copyright Holders: | Copyright © 2015 Cancer Research UK |
First Published: | First published in British Journal of Cancer 113(8):1140-1827 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record